Article

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: a meta-analysis

2023-10-28

Abstract excerpt

<h4>Background: </h4> The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for EGFR-mutated non-small cell lung cancer (NSCLC) is unclear. Previous studies have shown that EGFR-TKIs have excellent anti-tumor activity. However, almost all studies on neoadjuvant EGFR-TKI treatment for EGFR-mutated NSCLC have been non-randomized controlled trials with small...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3ecba581-1258-5e7c-9a4d-43910349bf9b
DOI: 10.21203/rs.3.rs-3444094/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: a meta-analysisDOI 10.21203/rs.3.rs-3444094/v1Read

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.Semantic proximity Read

Efficacy and safety of neoadjuvant targeted therapy in non-small cell lung cancer: a systematic review and meta-analysis.Semantic proximity Read

Efficacy and safety of adjuvant EGFR-TKIs for non-small cell lung cancer with EGFR mutations after surgery: an updated meta-analysisSemantic proximity Read

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.Semantic proximity Read

[Advances in neoadjuvant therapy for EGFR-mutant non-small cell lung cancer].Semantic proximity Read

Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review.Semantic proximity Read

Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.Semantic proximity Read

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read

Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers.Semantic proximity Read

[A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].Semantic proximity Read

Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read

Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.Semantic proximity Read